Articles related to ASCO

Explore new horizons in advanced hepatocellular carcinoma treatment with emerging data on lenvatinib and cisplatin’s potential efficacy as a second-line therapy and the promising triple combination therapy showing significant response rates.

Explore the latest insights from ASCO GU 2024 on first-line treatments for advanced renal cell carcinoma, including the effectiveness of combination therapies and the pressing need to address racial disparities in patient outcomes.

The Supreme Court’s deliberations on the Chevron deference and FDA’s drug approval authority underscore a critical juncture for healthcare delivery and regulatory practices, potentially reshaping physician autonomy and patient care standards.

Recent studies highlight the potential of cabozantinib plus atezolizumab in improving progression-free survival for mCRPC patients and confirm the benefits of high-dose radiotherapy in high-risk prostate cancer treatment, offering new insights into personalized care strategies.

Recent findings from the ASCO Gastrointestinal Cancers Symposium 2024 underscore the potential of innovative therapeutic combinations in enhancing outcomes for hepatocellular carcinoma patients, particularly those with unresectable or high-risk disease.

Pembrolizumab now represents a transformative advancement in the adjuvant treatment of clear cell renal cell carcinoma, significantly reducing the risk of progression or death by 38% compared to placebo.